To characterize the impact of increased production of TGF-b in a xenograft model of human breast cancer, TGF-b-responsive MDA-231 cells were genetically modi®ed by stable transfection so as to increase their production of active TGF-b1. Compared with control cells, cells that produced increased amounts of TGF-b proliferated in vitro more slowly. In vivo, however, tumors derived from these cells exhibited increased proliferation and grew at an accelerated pace. To evaluate the role of autocrine TGF-b signaling, cells were also transfected with a dominant-negative truncated type II TGF-b receptor (TbRII). Disruption of autocrine TGF-b signaling in the TGF-b-overexpressing cells reduced their in vivo growth rate. Co-inoculation of Matrigel with the TGF-b-overexpressing cells expressing the truncated TbRII compensated for their diminished in vivo growth capacity, compared with the TGF-b-overexpressing cells with an intact autocrine loop. Tissue invasion by the tumor was a distinctive feature of the TGF-b-overexpressing cells, whether or not the autocrine loop was intact. Furthermore, tumors derived from TGFb-overexpressing cells, irrespective of the status of the autocrine TGF-b-signaling pathway, had a higher incidence of lung metastasis. Consistent with the suggestion that TGF-b's enhancement of invasion and metastasis is paracrine-based, we observed no signi®cant dierences among the cell clones in an in vitro invasion assay. Thus, in this experimental model system in vitro assays of cell proliferation and invasion do not accurately re¯ect in vivo observations, perhaps due to autocrine and paracrine eects of TGF-b that in¯uence the important in vivo-based phenomena of tumor growth, invasion, and metastasis.
Introduction
TGF-b has been implicated as a critical cytokine in the development and progression of many epithelial malignancies, including breast cancer (for a review: Arrick and Derynck, 1996) . TGF-b exerts a wide variety of biological eects, in both autocrine and paracrine fashion. Some of its eects that could facilitate tumor growth and metastasis include increased expression of certain integrins, extracellular proteolysis, angiogenesis, and immune suppression Roberts et al., 1986; Wang et al., 1995; Torre-Amione et al., 1990; Inge et al., 1992; Matthews et al., 2000) . However, for normal mammary epithelium, TGF-b is a potent inhibitor of cell proliferation and in some circumstances even an inducer of apoptosis (Silberstein and Daniel, 1987; Nguyen and Pollard, 2000) . Indeed, increased expression of TGF-b in mammary gland epithelial cells of transgenic mice imparts a protective anti-carcinogenic eect (Pierce et al., 1995) . After a tumor has developed, however, the net eect of TGF-b can be considerably more complex. Diminished responsiveness of breast cancer cells to the autocrine growth inhibitory eects of TGF-b, coupled with an unabated paracrine in¯uence on host cells, may aect the tumor-host interaction so as to promote tumor growth.
We, and others, have reported data from immunohistochemical analyses of human breast cancers supporting the concept that increased production of TGF-b by the tumor cells is associated with metastasis and an overall worse clinical outcome (Gorsch et al., 1992; Ueki et al., 1993; Dalal et al., 1993) . While it has been suggested that at least some aspects of the promalignant impact of TGF-b on breast cancer cells may result from autocrine eects (Welch et al., 1990) , observations with other cell types suggest that paracrine eects predominate. Two groups have noted that increased production of TGF-b by tumor cells (a prostate cancer and a sarcoma cell line) that are themselves growth inhibited by TGF-b in in vitro proliferation assays nevertheless resulted in more vigorous in vivo growth when inoculated into an animal host (Steiner and Barrack, 1992; Chang et al., 1993) . Although these contrasting in vivo and in vitro consequences of increased TGF-b expression by tumor cells suggest that paracrine eects involving host cells more than compensate for the autocrine growth inhibitory eect, it is possible that autocrine eects of TGF-b are modulated by the speci®c growth conditions (Leone et al., 1991) . Two experimental interventions designed to diminish the impact of tumor-derived TGF-b, administration of neutralizing antibody and transfection of tumor cells with a soluble TGF-bbinding protein, resulted in attenuation of in vivo growth and metastasis in a xenograft nude mouse model with the human MDA-231 breast cancer cell line (Arteaga et al., 1993; Bandyopadhyay et al., 1999) . Neither of these approaches, however, can distinguish between autocrine and paracrine eects of TGF-b. In support of a paracrine-based mechanism for enhancement of in vivo tumor growth by TGF-b, Arteaga et al. (1993 Arteaga et al. ( , 1999 have provided evidence implicating an important paracrine immunosuppressive eect of TGFb on host natural killer cells.
The functional status of the TGF-b signaling pathway in primary human breast cancers has not been as well characterized. A correlation between diminished expression of the main TGF-b receptor (TbRII) by breast cancer cells and enhanced in vivo malignant behavior has been observed in studies based on patient specimens and an established cell line (Gobbi et al., 2000; Sun et al., 1994) , suggesting that attenuation of the growth-inhibitory TGF-b autocrine loop in breast cancers worsens clinical outcome. In support of the notion that diminished responsiveness to TGF-b facilitates tumor spread, Chen et al. (1998) identi®ed a somatic hypofunctional mis-sense mutation in the type I TGF-b receptor (TbRI) in two of 31 primary breast cancer specimens, and observed that nodal metastases were *six times more likely to contain this mutation. However, other investigators subsequently reported that this mis-sense mutation in TbRI was not found in a panel of metastatic lesions, including 20 breast cancer metastases (Anbazhagan et al., 1999) . Furthermore, the opposite conclusion regarding the role of autocrine TGF-b signaling in tumor metastasis arose from studies with colon and breast cancer cell lines transfected with a dominant-negative TbRII expression construct (Oft et al., 1998; Ye et al., 1999; McEarchern et al., 2001) , as well as from data from an experimental murine model of bone metastasis in which disruption of the TGF-b autocrine loop within the tumor cells inhibited metastatic formation and prolonged survival of the host (Yin et al., 1999) . Given that TGF-b1 gene transcription is positively regulated by TGF-b itself (Van Obberghen-Schilling et al., 1988) , this engineered loss of TGF-b signaling may have also signi®cantly diminished tumor cell secretion of TGF-b, and thereby also impacted paracrine eects in these in vivo experiments.
Our approach for elucidation of the relative importance of increased production of and/or diminished responsiveness to TGF-b is based on stable transfection of the MDA-231 breast cancer cell line with expression plasmids that direct production of active TGF-b and/or disrupt eective signaling. In this manner, we have been able to dissect and characterize the relative autocrine and paracrine components of TGF-b's eects in an in vivo model of tumor growth and metastasis. We observed a marked enhancement of in vivo tumor growth by tumor-derived TGF-b when the autocrine loop was left intact, even though TGF-b exerts a growth suppressive eect on these cells in vitro. Invasion of surrounding tissues by tumor cells was a feature of TGF-b-overexpressing tumor cells, regardless of the status of the autocrine TGF-b signaling loop, suggesting that paracrine-based mechanisms apply. Of note, in this tumor model system an in vitro assay of invasion did not faithfully re¯ect our in vivo observations.
Results
Generation and in vitro characterization of MDA-231 stable transfectants with altered TGF-b autocrine and/or paracrine signaling capacity
We designed mammalian expression plasmids for use in a sequential double transfection strategy to facilitate production of stable transfectants that overexpress active TGF-b ligand (C 2 S 2 -EZ), have diminished responsiveness to TGF-b (pCEN-TREZ), or both (C 2 S 2 -TREZ). Clones representing each of the four possible combinations from the double transfections (pCEN-EZ control cells, pCEN-TREZ, C 2 S 2 -EZ, and C 2 S 2 -TREZ) were selected for in vivo experiments with nude mice, and were further characterized in vitro by functional assays of TGF-b production, TGF-b responsiveness, and cell proliferation.
The production of TGF-b by the MDA-231 double transfectants was determined using a bioassay in which the active and total TGF-b released into the conditioned media of each clone was measured. As expected, both C 2 S 2 clones (C 2 S 2 -EZ and C 2 S 2 -TREZ) express high levels of TGF-b compared to the pCEN clones (approximately a 10-fold increase) (Table 1) . Furthermore, 40 ± 60% of the total TGF-b secreted by C 2 S 2 clones is biologically active, compared to less than 10% of the TGF-b secreted by the pCEN clones.
To verify that the truncated TbR-II functions eectively as a dominant negative inhibitor of TGFb signaling in TREZ-containing clones, the TGF-b responsiveness of the four MDA-231 double transfectants was characterized by luciferase assay using the TGF-b-responsive plasminogen activator inhibitor-1 (PAI-I) promoter reporter plasmid designated p800LUC. Brie¯y, cells were transfected with the p800LUC plasmid, then treated with or without exogenous TGF-b for 24 h, at which time cell lysates were prepared and assayed for luciferase activity (Figure 1) . The control clone, pCEN-EZ, remains TGF-b responsive as demonstrated by an increase in luciferase activity in TGF-b treated cells compared to the untreated control. The pCEN-TREZ and C 2 S 2 -TREZ clones show no induction of luciferase activity upon TGF-b treatment, indicating that the truncated TbR-II eectively blocks TGF-b signaling in these cells. Of note, the baseline luciferase production in these two clones is less than that in the pCEN-EZ clones, suggesting that the truncated TbR-II has also inhibited the TGF-b autocrine signaling loop in these cells. The C 2 S 2 -EZ clone shows only a minimal induction of luciferase activity upon the addition of TGF-b, but these cells have a high level of luciferase activity in the untreated cells, roughly equivalent to the pCEN-EZ cells treated with TGF-b. This suggests that the C 2 S 2 -EZ clone is producing such a high level of autocrine-active TGF-b that supplemental exogenous TGF-b has minimal additional eect on transactivation of the transfected p800LUC promoter construct.
In vitro anchorage-dependent growth rates of the MDA-231 double transfectants were determined by two methods. First, we calculated doubling times from hemocytometer-based counts of trypsinized cells at each clone passage over a period of 5 weeks (Table 1) . In this manner, we observed that both of the pCENderived clones grow faster than the C 2 S 2 clones. The C 2 S 2 -EZ clone grew the slowest, likely a re¯ection of the fact that it produces considerable amounts of active TGF-b while maintaining a functional receptor complex. Because signi®cant dierences in plating eciency could confound such doubling time comparisons, we also measured the rate of increase in cell number 1 ± 3 days after plating. Compared with the pCEN-EZ control cells, only the C 2 S 2 -EZ cells proliferated at a rate that was signi®cantly slower (36% of control; P50.05). Anchorage-independent growth of the clones was evaluated by a soft agar colony formation assay. In this assay both C 2 S 2 -based clones yielded fewer and smaller colonies, compared with the pCEN-derived clones (not shown). The diminished growth of C 2 S 2 -TREZ cells when embedded within soft agar suggests that complete disruption of the autocrine loop has not been achieved, such that some residual autocrine growth inhibition is observed at the elevated local concentrations of TGF-b resulting from these culture conditions.
Increased expression of TGF-b correlates with an enhanced rate of tumor growth in vivo
The in vivo tumorigenicity of the MDA-231 double transfectants was evaluated in a xenograft model of human breast cancer. Inoculation of athymic nude mice subcutaneously in the rear¯ank with 3610 6 cells resulted in primary tumor formation in all animals. Growth curves for the subcutaneous tumors from the four clones are presented in Figure 2a . In sharp contrast to our in vitro observations, tumors from the two TGF-b-overexpressing clones grew at rates that exceeded the growth rate of tumors from the pCEN-EZ and pCEN-TREZ clones. Furthermore, comparing the two C 2 S 2 -based clones, the tumors derived from the cells transfected with the truncated TbRII (C 2 S 2 -TREZ) demonstrated a considerably slower rate of growth. These data suggest that increased expression of TGF-b can accelerate in vivo tumor growth of breast cancer by an autocrine-based mechanism, even though in in vitro cell culture TGF-b causes growth inhibition.
Matrigel, a complex mixture of extracellular matrix and cytokines which forms a gel at or above room temperature, has been used to enhance the in vivo tumorigenicity of human tumor cells in nude mice, although its mechanism of action is unknown (Noel et Conditioned media from cell cultures was analysed for active and total (active plus latent) TGF-b using a bioassay, as described in Materials and methods.
b Derived from cell counts over a month-long period of routine cell culture in medium containing 10% serum. c Proliferation rates of the clones were measured in parellel and normalized to pCEN-EZ control cells Figure 1 Truncated TbR-II functions eectively as a dominant negative inhibitor of TGF-b signaling in MDA-231 cells. MDA-231 double transfectants were transiently transfected with the luciferase reporter plasmid p800LUC and an expression construct for GFP. Following transfection, the cells were treated with 5 ng/ ml TGF-b for 24 h (stippled bars), or left untreated (®lled bars), and then protein lysates were harvested. The lysates were assayed for luciferase activity and normalized to GFP¯uorescence to correct for transfection eciency. This ®gure represents average values of three separate transfection experiments, each with the untreated pCEN-EZ sample set to 1.0. Error bars indicate standard error of the mean (s.e.). A statistically signi®cant increase in luciferase production following treatment with TGFb was evident with the vector-control pCEN-EZ cells, but not with the other clones (P=0.021). Signi®cant dierences between the clones in the absence of additional TGF-b included pCEN-EZ to pCEN-TREZ (P=0.029), and C 2 S 2 -EZ to C 2 S 2 -TREZ (P=0.013) al., 1993; Bao et al., 1994; Mullen et al., 1996) . To evaluate the eect of Matrigel on our cell clones, we performed a parallel series of inoculations of mice with an equal number of tumor cells mixed 50 : 50 with liquid Matrigel. The inclusion of Matrigel increased the in vivo growth rates for all four clones ( Figure 2b ). Matrigel is known to contain a number of potential growth factors, including TGF-b (Vukicevic et al., 1992) . Of note in this regard, our data indicate that disruption of TGF-b signaling did not diminish the tumor-promoting eect of Matrigel. Indeed, the two TREZ-derived clones exhibited greater relative increases in tumor growth when inoculated with Matrigel, compared with their TGF-b-responsive counterparts. Addition to Matrigel to the C 2 S 2 -TREZ cells resulted in tumor growth rates that were similar to those seen with the C 2 S 2 -EZ cells, suggesting that Matrigel can compensate for an important autocrine eect of TGF-b that is otherwise not exhibited by the C 2 S 2 -TREZ cells.
At the conclusion of the in vivo growth experiments mice were sacri®ced and the tumors removed by blunt dissection and weighed. The ®nal weights of the resected tumors are consistent with the volume measurements made in the living tumor-bearing animals ( Figure 2c ). Towards the end of the experiment, many of the mice bearing C 2 S 2 -EZ tumors exhibited systemic toxicity, manifested by cachexia and/or ascites. In vivo tumor cell proliferation rates in the pCEN-EZ and C 2 S 2 -EZ tumors were compared in a parallel cohort of mice (eight mice per group). Mice were sacri®ced 2 weeks after inoculation and the tumors examined by immunohistochemistry for expression of the Ki-67 antigen, a marker of cell proliferation. In the pCEN-EZ-derived tumors 16% of tumor cells were Ki-67-positive (+4 s.d.). In contrast, 37% (+3 s.d.) of the C 2 S 2 -EZ tumor cells were Ki-67-positive. Thus, much if not all of the increased rate of in vivo tumor growth by the TGF-b-overexpressing cells is due to increased cell proliferation.
Primary tumors from TGF-b overexpressing clones are more locally invasive
Histologic examination of the primary tumors revealed marked dierences in pathology, both gross and microscopic. In seven of 48 mice inoculated with C 2 S 2 -derived clones (C 2 S 2 -EZ and C 2 S 2 -TREZ) there was hemorrhagic ulceration of the skin overlying the primary tumor, whereas there were no such ulceration of tumors originating from pCEN clones. Grossly, the two pCEN-derived clones gave rise to tumors that were easy to dissect away from the surrounding tissues, had smooth glistening surfaces that resembled pearls, and exhibited a ®rm, homogeneous, cream-colored interior upon cross-section. In contrast, tumors from C 2 S 2 -derived clones lacked a well-de®ned interface between tumor and normal tissue, and therefore were more dicult to dissect out. In addition, on cross-section they were heterogeneous in color and consistency, with areas of hemorrhage and frequently with lique®ed centers. These characteristic dierences between the pCEN and C 2 S 2 tumors were not aected by the presence or absence of Matrigel.
Microscopic analysis of H+E-stained slides of the primary tumors con®rmed our gross observations. The pCEN-derived tumors contained viable tumor cells throughout (Figure 3a ) whereas the C 2 S 2 -derived TGFb-overexpressing tumors typically consisted of a band of viable tumor cells surrounding an area of central necrosis (Figure 3b ). Considering the possibility that the necrosis we observed in the C 2 S 2 tumors was a function of their larger size, we speci®cally compared selected p-CEN and C 2 S 2 tumors that had reached equivalent size. By this comparison, we were able to conclude that this feature of central necrosis was not simply a function of size; p-CEN tumors that were as large as C 2 S 2 tumors were nonetheless viable throughout. Histologic examination of the interface between tumor and surrounding tissue con®rmed notable dierences between the pCEN tumors and the TGF-b overexpressing C 2 S 2 tumors, as suggested by our gross observations. Tumors derived from the pCEN clones were minimally invasive and typically surrounded by a pseudocapsule (indicated by an arrow in Figure 3a) . In contrast, the C 2 S 2 tumors lacked a pseudocapsule and were locally invasive into surrounding muscle and fat (Figure 3b,c) . Figure 3c shows a section of a C 2 S 2 tumor that had ulcerated and invaded through the skin. We observed similar histologic ®ndings in a preliminary series of in vivo experiments involving independently-generated TGF-b-overexpressing and control-transfected clones of MDA-231 cells. It is worth emphasizing that tumors derived from the C 2 S 2 -EZ and C 2 S 2 -TREZ cells were indistinguishable in terms of local invasion and central necrosis, suggesting that these aspects of tumor formation are consequences of TGF-b acting in a paracrine fashion.
TGF-b overexpressing tumors are more metastatic
To evaluate the eect of alterations in TGF-b production and/or responsiveness on the metastatic capability of a tumor, we measured the incidence and burden of metastatic disease in mice inoculated with each of the four MDA-231 double transfectant clones. By microscopic examination of various organs from tumor-bearing mice, we detected metastatic deposits in lung tissue from some animals, but did not observe metastases in liver, spleen, or other sites. Metastatic involvement was not evident by gross inspection of the lung surfaces, as is often the case in murine models of metastatic disease. Rather, metastatic deposits were limited to microscopic foci, typically composed of 5 ± 50 tumor cells in a perivascular cluster. We based our determination of the presence of metastatic disease on the detection of plasmid-derived sequence, speci®c to the vectors used to generate the stably transfected tumor cells, using genomic DNA prepared from mouse tissues as the template DNA for PCR ampli®cation. In agreement with our histologic examinations, we occasionally detected tumor-derived DNA in genomic DNA prepared from lung tissue of tumor-bearing mice, but not from other sites, such as liver. Table 2 provides a summary of our results regarding the occurrence of metastatic disease in the lungs of mice inoculated with each clone. These data indicate that the TGF-boverexpressing clones displayed a higher incidence of metastatic spread than the non-overexpressing pCEN clones. The total incidence for pCEN-EZ was eight of 24 whereas C 2 S 2 -EZ tumors metastasized in 15 of 20 cases, a dierence that is statistically signi®cant (P50.01). Similarly, the total incidence of metastasis in pCEN-TREZ was three of 23, while that of C 2 S 2 -TREZ was 14 of 24, also a statistically signi®cant We assessed the burden of pulmonary metastatic disease based on a semi-quantitative determination of the proportion of tumor-derived DNA in the genomic DNA isolated from lung tissue from each mouse. In each PCR/Southern assay, we concurrently analysed a dilution series of tumor cell DNA mixed with normal murine DNA, and by interpolation of the PCR product intensities on the Southern blot we estimated metastatic load, such that a value of 0.1% means that *0.1% of the genomic DNA harvested from the lung of that animal was tumor-derived. An example of this assay is provided in Figure 4a . By this approach, we reproducibly detected metastatic disease corresponding to burdens ranging from 0.0003 to 3%. Assessment of metastatic burden by this method generally agreed with microscopic examination of random H+E-stained sections of lung tissue, although occasional samples in which metastatic cells were not found microscopically yielded positive results by PCR, albeit at low levels of metastatic involvement. Given this wide range in metastatic burden, to facilitate proper statistical comparison of the groups a logarithmic transformation of the data was performed (Figure 4b ). The greatest lung metastatic burden was seen in animals bearing C 2 S 2 -EZ tumors, with little eect evident from the inclusion of Matrigel in the primary inoculation. By comparison, the addition of Matrigel to the C 2 S 2 -TREZ cells largely compensated for any attenuation in metastatic capacity secondary to defective TGF-b signaling, just as it did for primary tumor growth of these cells. The greater metastatic tumor burden associated with the C 2 S 2 -EZ-derived tumors, as well as their propensity to be more invasive at the primary tumor site, compared with tumors with pCEN-EZ cells, suggested that they were able to metastasize at an earlier time point. We assessed early metastasis by sacri®cing a cohort of animals 2 weeks after subcutaneous inoculation of tumor cells. Metastatic disease was already evident just 2 weeks after tumor inoculation in three of the eight mice with C 2 S 2 -EZ tumors, but in none of the eight mice with pCEN-EZ tumors (P=0.064).
In vivo invasiveness does not correlate with in vitro assays of invasion through type I collagen
The pathologic feature of extensive local invasion at the primary tumor site was equally evident in tumors derived from the C 2 S 2 -EZ and C 2 S 2 -TREZ cells. This suggested that in vivo invasion in this xenograft model is a manifestation of paracrine eects of TGF-b on neighboring host cells. To clarify this matter further, we characterized the inherent invasive capacity of our clones in an in vitro assay. In vitro invasiveness of each clone was measured using an invasion chamber assay in which a nitrocellulose ®lter coated with type I Cells were inoculated subcutaneously in serum-free medium alone (7) or in a 1:1 mixture of serum-free medium and liquid matrigel (+). b Incidence is based on detection of tumor-speci®c DNA in genomic DNA prepared from lungs of tumor-bearing mice, as described in Materials and methods collagen was used to separate the two chambers. The results of a representative invasion assay are shown in Figure 5a , in which the per cent¯uorescence, a measure of cell number, is plotted against invasion depth. The pCEN-EZ clone was slightly more invasive than the others, with a small percentage of cells reaching depths 410 mm. The average invasion scores of each clone based on three independent invasion assays were determined and are shown in Figure 5b . There are minor dierences among the four clones, with pCEN-EZ having the highest invasion score, however these dierences are not statistically signi®-cant. These data are consistent with our in vivo observations suggesting that the in¯uence of TGF-b on invasion is primarily a paracrine eect.
Discussion
The development and progression of malignancy is a complex multi-step process involving a multitude of cytokines, aecting the complex behaviors and interactions of many diverse cells, of both tumor and host. It is therefore understandable that a pluripotent cytokine such as TGF-b would be implicated as an important player in a wide range of cancer-related phenomena. A commonly accepted conceptualization of the role of TGF-b in epithelial malignancies, such as breast cancer, is that in the pre-malignant phase TGFb's autocrine anti-proliferative eect predominates, and the TGF-b system serves a tumor suppressive function. Later, however, the balance shifts and TGF-b promotes tumor progression and spread (Koli and Arteaga, 1996; Reiss and Barcellos-Ho, 1997) . Though examples exist in which a cell's proliferative response to TGF-b switches from inhibition to stimulation in parallel with tumor progression (Hsu et al., 1994; Matsuzaki et al., 2000) , attenuation of the autocrine loop by decreased expression of the TbRII receptor, leaving intact paracrine signaling to host cells is a frequently-implicated paradigm. Consistent with this formulation of the role of TGF-b in cancer, an association between increased production of TGF-b by tumors and worse clinical outcome has been noted for many epithelial cancers (Gorsch et al., 1992; Takanami et al., 1994; Friedman et al., 1995; Kinugasa et al., 1998; WikstroÈ m et al., 1998; Maehara et al., 1999; Saito et al., 1999) . The experiments outlined in this study were designed to contrast in vivo and in vitro consequences of altered tumor cell TGF-b expression and responsiveness, and distinguish between autocrine and paracrine eects.
The most dramatic result of increased TGF-b production was an enhancement of in vivo tumor growth, despite an intact autocrine loop that manifests itself by decreased proliferation in vitro. As noted in the introduction, previous investigators have reported similar observations with other cell types, but could not determine whether autocrine or paracrine eects underlie the increased rate of in vivo tumor growth (Steiner and Barrack, 1992; Chang et al., 1993) . Our data with the MDA-231 cell line suggest that a signi®cant component of the accelerated in vivo growth of TGF-b-overexpressing tumors is autocrine in nature and largely due to an increased rate of proliferation. It is important to keep in mind that dierent cell lines might yield contrasting results. For instance, working with a line of MCF-7 cells with diminished responsiveness to TGF-b, other investigators have reported that restoration of the autocrine loop by re-expression of TbRII resulted in attenuation of in vivo growth potential (Sun et al., 1994) .
A potentially informative clue regarding the nature of the autocrine-based enhancement of in vivo growth by TGF-b comes from the growth rates of tumors when Matrigel was included with the initial subcutaneous tumor cell inoculum. Simply stated, Matrigel compensated for attenuation of the TGF-b autocrine loop. The observation that Matrigel can enhance the growth of tumors has been reported for many dierent tumor types, though the mechanism by which this happens has not been established (Noel et al., 1993; Bao et al., 1994; Mullen et al., 1996) . The fact that Matrigel contains TGF-b, as well as other cytokines and extracellular matrix proteins, might suggest that the TGF-b within Matrigel accounts for much of its tumor promoting activity (Vukicevic et al., 1992) . Our observations are not consistent with this notion, since cells with a 10-fold increased rate of TGF-b production, and therefore clearly not lacking for TGF-b, showed the greatest growth enhancement when coinoculated with Matrigel. In future experiments we will compare standardly-prepared Matrigel with a growth factor-depleted formulation of Matrigel for its ability to compensate the C 2 S 2 -TREZ cells for their defective autocrine loop. In that manner, we might acquire evidence indicating whether it is TGF-b's autocrine in¯uence vis-aÁ-vis production of extracellular matrix components or other important cytokines that facilitates in vivo tumor growth.
At necropsy, we observed that the pCEN-based tumors were easy to dissect away from the normal mouse tissue, probably because of their tendency to form a pseudocapsule around the tumor and not invade into surrounding areas. In contrast, the TGF-boverexpressing tumors, C 2 S 2 -EZ and C 2 S 2 -TREZ alike, tended to spread invasively into the surrounding fat, muscle, and skin. This suggests that the locally invasive phenotype of these tumors is primarily a paracrinebased phenomenon. Our ®ndings regarding the in vitro invasive capacity of the various clones are consistent with the conclusion that TGF-b augments tumor cell invasiveness by a paracrine mechanism. That said, the molecular basis of this complex phenotype, as well as the identity of the host cell type aected by tumor derived TGF-b, remains undetermined.
As expected, the rapidly growing and locally invasive tumors were associated with the greatest amount of metastatic spread. At baseline levels of TGF-b production, suppression of autocrine signaling did appear to reduce metastasis, consistent with the work of others (Oft et al., 1998; Ye et al., 1999; McEarchern et al., 2001; Yin et al., 1999) . It would be informative to compare our current observations with those that would result from MDA-231 cells with a constitutivelyactivated autocrine loop but without a parallel increase in TGF-b secretion that would also augment paracrine eects. For instance, cells transfected with a constitutively active TbRI or Smad protein might form rapidly growing tumors, to the extent that in vivo growth rate is an autocrine-only phenotype, yet be poorly invasive. If so, determination of the metastatic capacity of such cells might shed light on the relative importance of rapid primary tumor growth vs local invasion and other paracrine eects.
In summary, we have shown that whereas enhancement of tumor invasion is likely a paracrine-based eect of TGF-b, augmentation of the rate of in vivo tumor growth is largely autocrine-based. Thus, while there may be a cancer-predisposing consequence to the loss of TGF-b responsiveness on the part of premalignant mammary epithelium, this xenograft model system suggests that loss of TGF-b responsiveness is not a prerequisite for tumor progression. Clinically relevant consequences of autocrine-based TGF-b activity may also be important in other contexts, e.g. as a determinant of response to therapy. For example, decreased autocrine signaling of TGF-b has been reported to augment sensitivity of breast cancer cells to certain cytotoxic chemotherapy agents, and reduce susceptibility to cytotoxicity mediated by tumor necrosis factor-a (Ohmori et al., 1998; Tobin et al., 2001 ).
Materials and methods

Plasmid DNA construction and isolation
We used a bicistronic plasmid strategy (Ghattas et al., 1991) to obtain stable transfectants overexpressing active TGF-b and/or a truncated TbR-II. To accomplish this, we constructed plasmids, designated C 2 S 2 and TREZ, that direct transcription of a bicistronic mRNA encoding TGF-b ligand (Brunner et al., 1989) or a truncated TbR-II, respectively, followed by the internal ribosomal entry site (IRES) of the encephalomyocarditis virus upstream of the coding sequence of a selectable marker gene. The C 2 S 2 -based plasmid contains human TGF-b1 cDNA sequence with two cysteine-to-serine mutations in the pro-domain that disrupt the stability of the latent complex and result in the production of biologically active TGF-b (Brunner et al., 1989) . The TREZ construct directs the expression of a truncated human TbR-II cDNA, which contains the entire extracellular and transmembrane domains of the receptor but lacks the cytoplasmic kinase domain. This truncated TbR-II has been shown by others to function eectively as a dominant negative inhibitor of the TGF-b signaling cascade (Brand and Schneider, 1995) . All expression plasmids use the cytomegalovirus promoter/ enhancer to drive expression. Construction of the TREZ plasmid started with subcloning the 830 bp NcoI-BglII fragment of the TbR-II cDNA clone H2-3FF (Lin et al., 1992) was subcloned into the EcoRI-BamHI sites of pRK5 (Genentech). The resulting plasmid was cut at XbaI and SalI sites downstream of the truncated TbR-II sequence and used in a three-way ligation for the addition of the 599 bp XbaINcoI fragment from LZIN (Ghattas et al., 1991) , containing the IRES, and the 429 bp NcoI-SalI fragment from pZeoSV (Invitrogen) containing the coding sequence for the zeocin resistance gene. The control plasmid, designated EZ, was created by removal of the truncated receptor sequence from the TREZ plasmid by EcoRI digestion and re-closure by intramolecular ligation. The C 2 S 2 plasmid and its control plasmid, pCEN, were derived from the pCEN/MER plasmid, the kind gift of Dr John E Majors (Ghattas et al., 1991) . We prepared the pCEN construct from pCEN/MER by EcoRI digestion followed by reclosure of the vector by intramolecular ligation, leaving the IRES and neomycin resistance gene intact. The C 2 S 2 plasmid was then prepared by subcloning the coding sequence of TGF-b1 containing the C 2 S 2 mutation into the pCEN vector upstream of the IRES. Speci®cally, the coding sequence was removed from the pRK5-C 2 S 2 vector with BglII and EcoRI and the pCEN plasmid was linearized with EcoRI. Both linearized DNA fragments were blunted with Klenow and ligated to yield the C 2 S 2 bicistronic construct used in these studies. All plasmid DNAs were puri®ed using plasmid column chromatography kits (Qiagen).
Cell culture and stable transfection
The human breast cancer cell line MDA-231 was obtained from American Type Culture Collection and maintained in DMEM/F12 supplemented with 10% fetal bovine serum, 2.5 mM L-glutamine, 100 IU/ml penicillin, and 100 mg/ml streptomycin at 378C, 5% CO 2 . Double transfectants were generated in a two step manner. First, cells were transfected with 15 mg of either the C 2 S 2 plasmid or control plasmid, pCEN, by calcium phosphate-mediated transfection (Ausubel et al., 1987) followed by selection in media containing 400 mg/ml geneticin. Stable clones were isolated and assayed for TGF-b production. C 2 S 2 and pCEN clones were then transfected with the expression plasmid TREZ or control plasmid EZ in like manner, followed by selection in media containing 50 mg/ml zeocin and 400 mg/ml geneticin. The resulting drug resistant colonies were isolated and assayed by Western analysis for expression of the truncated TbR-II (Tobin et al., 2001) . The TREZ-transfected clones used in these studies expressed at least 10-fold more truncated TbR-II than the endogenous full-length receptor. Thus, we have generated four types of MDA-231 cell clones: control-plasmid transfected cells (pCEN-EZ), cells with a disruption in TGFb autocrine signaling (pCEN-TREZ), cells that overexpress TGF-b but were not transfected with the dominant negative truncated TbRII (C 2 S 2 -EZ), and TGF-b overexpressing cells with a disrupted autocrine loop (C 2 S 2 -TREZ).
Assays of TGF-b responsiveness and production
Cells were plated in 10 cm dishes and transfected with 7.5 mg of the TGF-b responsive p800LUC plasmid, in which luciferase expression is driven by an 800 bp segment from the promoter for PAI-I (the kind gift of D Rifkin (Abe et al., 1994) ), and 1.5 mg of an expression plasmid for green uorescent protein (GFP) by lipofectAMINE (Life Technologies). The following day each dish was trypsinized, the cells aliquoted into two 6 cm dishes, then treated for 24 h with 0 or 5 ng/ml TGF-b. Lysates were prepared and analysed for luciferase activity, as described (Lu and Arrick, 2000) . Luciferase activity of each sample was normalized to the amount of GFP¯uorescence in the lysate, which was assessed by analysing 80 ml aliquots of the lysate in a¯uorimeter with excitation wavelength at 485 nm and emission wavelength at 508 nm.
We determined the TGF-b production of the MDA-231 stable clones with a bioassay of conditioned media. Cells were plated in a 24-well plate at densities of 1 ± 3610 5 cells/ well. The following day, at 50 ± 75% con¯uence, wells were washed twice then incubated with 800 ml of serum-free DMEM/F12 containing 0.3 mg/ml of bovine serum albumin at 378C, 5% CO 2 for 24 h, at which time conditioned media was harvested on ice. To the remaining cell monolayer, 200 ml of 0.1 N NaOH was added to each well and later analysed for protein content. Half of each sample of conditioned media was heated to 808C for 5 min to activate any latent TGF-b in the conditioned media. The TGF-b bioactivity in the conditioned media was determined using mink lung epithelial cells that are stably transfected with a p800LUC-derived construct (Keeton et al., 1991; Abe et al., 1994) . These indicator cells were plated at 1.6610 4 cells per well in a 96-well plate and incubated at 378C, 5% CO 2 for 3 h. Samples of unactivated and heat activated conditioned media were added to the cells at various dilutions for a ®nal volume of 100 ml/well. After a 16 h incubation, the wells were washed with PBS, cells lysed in 100 ml of luciferase lysis buer and assayed for luciferase activity, as described above. A standard curve was generated with each experiment using recombinant active TGF-b. All values were normalized to protein content of the cell monolayer that conditioned the media, assessed by the bicinchoninic acid-based protein assay (Pierce).
In vitro cell proliferation
To determine the doubling time of individual clones, each clone was counted on a hemocytometer and plated in tissue culture¯asks at 10 ± 20% con¯uence. Cells were incubated at 378C, 5% CO 2 for 3 ± 4 days, then trypsinized and recounted once the¯asks reached 70 ± 80% con¯uence. The change in cell number and the elapsed time were used to determine the cell doubling times. The values in Table 1 are averages of 10 such determinations per clone. Relative rates of proliferation of the clones were determined by measuring the change in viable cell number between 1 and 3 days following plating. Cells were trypsinized, counted, and then plated in duplicate 96-well plates in triplicate at 8000 cells/well. Plates were analysed by the Celltiter MTS reduction assay kit (Promega) according to the manufacturer's instructions, and the increase in cell number over the 2 day period calculated relative to the pCEN-EZ control cells. The values in Table 1 are averages of three such determinations per clone.
In vitro cell invasion assay
In vitro tumor cell invasiveness was evaluated by an invasion chamber assay, as described (Benbow et al., 1999) . Brie¯y, a nitrocellulose ®lter coated with collagen type I was used to separate the two compartments of the invasion chamber. Single cell suspensions of 10 5 cells were cultured on the type I collagen in the upper compartment for 48 h at 378C and 5% CO 2 . The membranes were washed in PBS, dehydrated in 2-propanol and treated with RNase (1 mg/ml) for 30 min at room temperature. Following a second wash in PBS, the membranes were stained with propidium iodide (0.01 mg/ml) for 30 min at room temperature. The degree of cellular invasion was assessed by measuring propidium iodidē uorescence of cell nuclei within the collagen-coated membranes using confocal laser scanning microscopy at 2 mm increments starting at the top of the collagen matrix. For each assay, a minimum of four ®elds/®lter was analysed. Invasion scores for each of the double transfectants was calculated as the sum of the per cent¯uorescence at each depth multiplied by the square root of the depth.
In vivo studies
Athymic female nude (nu/nu) mice were obtained from Jackson Laboratories (strain NU/J). When 6 ± 7 weeks old, each mouse received a subcutaneous injection of 3610 6 cells in 200 ml in the right rear¯ank. For tumor cell inoculation, cells were trypsinized, counted, and suspended in cold DMEM/F12 media without serum or antibiotics to a ®nal cell density of 30610 6 cells/ml. This cell suspension was then mixed with an equal volume of cold (48C) liquid Matrigel basement membrane matrix (Collaborative Biomedical Products), or DMEM/F12 media, and injected into the mice within 15 min. Following injection, the mice were monitored for the formation of a primary tumor at the injection site. The largest diameter (L) and smallest diameter (S) of each tumor were measured weekly with calipers, and tumor volumes calculated (Volume=L6S 2 60.52) (Van Slooten et al., 1995) . Five weeks after injection the mice were sacri®ced and examined. Because of an obvious moribund state, in accordance with animal use protocols, 15 of the 24 mice injected with C 2 S 2 -EZ cells were sacri®ced prior to the 5-week end-point. The primary tumors were carefully excised and weighed, and genomic DNA was harvested from the liver and lung of each tumor-bearing mouse using the Puregene DNA isolation kit according to the manufacturer's instructions (Gentra Systems). In addition, tissue samples of the primary tumor, lung and liver were ®xed in 10% buered formalin and paran-embedded for histological examination of hematoxylin and eosin (H+E) stained sections.
The proliferation index of the xenograft tumors was determined by immunohistochemical analysis of formalin®xed sections with a monoclonal antibody speci®c for the proliferation marker Ki-67 (MIB-1 from Immunotech), used at a 1 : 1000 dilution after antigen retrieval by a 30 min incubation in citrate buer in a steam chamber. The horseradish peroxidase/3,3'-diaminobenzidine detection kit from Biogenex was used to visualize immunoreactivity. The sections were counterstained with hematoxylin and the average of at least 500 tumor cells from each of the specimens was counted, yielding the percentage of Ki-67-positive nuclei.
PCR-based detection of metastatic spread
To detect and quantitate the metastatic tumor burden in each mouse, DNA from lung and liver tissue was used as template in a PCR reaction using primers directed against vector sequence. Speci®cally, 100 ng of DNA was used as template in each 30 ml PCR reaction containing 0.2 mM of each dNTP, 1 mM of each primer, 1 mM MgCl 2 and 1 U of Platinum Taq DNA Polymerase (Gibco) in 16 PCR buer II (Perkin Elmer). Denaturing of the template at 958C for 4 min was followed by 36 cycles of 948C for 1 min, 608C for 45 s, and 728C for 1 min. The reaction was completed with 10 min of extension at 728C. The 5' primer (TCCTCAAGCGTATT-CAACAA) targets sequence within the IRES of the bicistronic plasmid, while the 3' primer (ACACGACCTCC-GACCACTC) is speci®c for sequence within the zeocin resistance gene of the vector. The expected 433 bp PCR product was then detected by Southern analysis (Ausubel et al., 1987) using the 454 bp HindIII fragment of the EZ vector. The quality of the genomic DNA preparations of all samples giving negative results was con®rmed by PCR ampli®cation of the mouse p53 gene. For quantitation purposes, a standard curve was generated using a dilution series of DNA (0.0003 to 30%) from each clone, diluted with mouse genomic DNA. Each Southern blot was scanned and the intensity of the bands was quantitated using IPLab Gel software. The tumor burden of each sample was then determined by linear interpolation.
Statistical analysis
Statistical signi®cance of the experimental data was determined using the two-tailed, unpaired Student's t-test or the two-tailed Welch's alternate t-test where appropriate. For statistical analysis of the metastatic burden percentages obtained through PCR and Southern blot, these data were logarithmically transformed (log (10006+1)). The transformed data were evaluated using the two-tailed, unpaired Mann-Whitney test. Metastatic incidences rates from the cell clones were compared by the Chi squared test.
